DCTH · Delcath Systems, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.99M | - | $20.56M | $24.16M | $19.78M | - | $11.20M | $7.77M | $3.14M | - |
| Cost of Revenue | $3.74M | - | $2.62M | $3.32M | $2.85M | - | $1.64M | $1.52M | $903.0K | - |
| Gross Profit | $21.26M | - | $17.94M | $20.84M | $16.94M | - | $9.56M | $6.25M | $2.24M | - |
| R&D | $9.82M | - | $7.99M | $6.88M | $5.01M | - | $3.87M | $3.39M | $3.70M | - |
| SG&A | $13.07M | - | $10.34M | $11.37M | $11.29M | - | $6.95M | $6.76M | $8.81M | - |
| Total Operating Expenses | $22.89M | - | $18.33M | $18.25M | $16.30M | - | $10.82M | $10.16M | $12.51M | - |
| D&A | $102.0K | - | $100.0K | $100.0K | $43.0K | - | $100.0K | $100.0K | $29.0K | - |
| Operating Income | ($1.64M) | - | ($388.0K) | $2.59M | $642.0K | - | ($1.26M) | ($3.91M) | ($10.28M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $162.0K | - | ($455.0K) | $508.0K | $0 | - | - | - | - | - |
| Net Income | ($1.07M) | - | $830.0K | $2.70M | $1.07M | - | $1.86M | ($13.74M) | ($11.11M) | - |
| EPS - Basic | ($0.03) | - | $0.02 | $0.08 | $0.03 | - | $0.06 | ($0.48) | ($0.45) | - |
| EPS - Diluted | ($0.03) | - | $0.02 | $0.07 | $0.03 | - | $0.06 | ($0.48) | ($0.45) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41.31M | $43.45M | $41.81M | $34.42M | $12.78M | $32.41M | $8.31M | $14.78M | $11.76M | $12.65M |
| Accounts Receivable | $14.16M | $11.74M | $13.75M | $15.84M | $13.94M | $10.89M | $6.94M | $3.73M | $1.56M | $241.0K |
| Inventory | $9.81M | $10.25M | $10.74M | $10.52M | $7.13M | $6.93M | $6.64M | $6.32M | $3.63M | $3.32M |
| Accounts Payable | $3.46M | $2.66M | $2.13M | $4.72M | $1.62M | $961.0K | $937.0K | $3.28M | $1.49M | $1.01M |
| Current Assets | $120.27M | $119.53M | $120.61M | $113.48M | $84.35M | $73.76M | $28.88M | $31.40M | $33.65M | $37.16M |
| Total Assets | $124.84M | $123.63M | $124.30M | $116.88M | $87.32M | $76.59M | $31.68M | $33.91M | $36.10M | $38.61M |
| Current Liabilities | $10.70M | $10.95M | $8.01M | $10.44M | $5.29M | $6.14M | $21.58M | $12.29M | $13.34M | $16.45M |
| Long-term Debt | - | - | - | - | - | $0 | $2.00M | $4.49M | $7.36M | $10.15M |
| Total Liabilities | $12.13M | $12.41M | $9.45M | $11.89M | $7.09M | $7.84M | $23.11M | $29.72M | $21.48M | $22.84M |
| Stockholders' Equity | $112.71M | $111.22M | $114.85M | $104.99M | $80.23M | $68.75M | $8.57M | $4.19M | $14.62M | $15.78M |
| Retained Earnings | ($529.92M) | ($528.85M) | ($526.95M) | ($527.78M) | ($530.48M) | ($531.55M) | ($528.15M) | ($530.01M) | ($516.27M) | ($505.16M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $857.0K | - | - | - | $2.20M | - | - | - | ($9.58M) | - |
| Investing Cash Flow | ($571.0K) | - | - | - | ($25.15M) | - | - | - | $4.66M | - |
| Financing Cash Flow | ($2.38M) | - | - | - | $3.25M | - | - | - | $4.02M | - |
| CapEx | $570.0K | - | - | - | $140.0K | - | - | - | $13.0K | - |
| Free Cash Flow | $287.0K | - | - | - | $2.06M | - | - | - | ($9.60M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 85.1% | - | 87.2% | 86.3% | 85.6% | - | 85.4% | 80.4% | 71.2% | - |
| Operating margin | -6.5% | - | -1.9% | 10.7% | 3.2% | - | -11.2% | -50.4% | -327.4% | - |
| EBITDA margin | -6.1% | - | -1.4% | 11.1% | 3.5% | - | -10.3% | -49.1% | -326.5% | - |
| Net margin | -4.3% | - | 4.0% | 11.2% | 5.4% | - | 16.6% | -176.9% | -354.0% | - |
| Free cash flow margin | 1.1% | - | - | - | 10.4% | - | - | - | -305.7% | - |
| FCF / Net income | -0.27 | - | - | - | 1.93 | - | - | - | 0.86 | - |
| R&D / Revenue | 39.3% | - | 38.8% | 28.5% | 25.3% | - | 34.5% | 43.7% | 117.9% | - |
| SG&A / Revenue | 52.3% | - | 50.3% | 47.1% | 57.1% | - | 62.1% | 87.1% | 280.8% | - |
| Effective tax rate | - | - | -121.3% | 15.9% | 0.0% | - | - | - | - | - |
| Return on assets | -0.9% | - | 0.7% | 2.3% | 1.2% | - | 5.9% | -40.5% | -30.8% | - |
| Return on equity | -0.9% | - | 0.7% | 2.6% | 1.3% | - | 21.7% | -327.8% | -76.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 11.24 | 10.92 | 15.06 | 10.88 | 15.95 | 12.01 | 1.34 | 2.55 | 2.52 | 2.26 |
| Quick ratio | 10.33 | 9.98 | 13.71 | 9.87 | 14.61 | 10.88 | 1.03 | 2.04 | 2.25 | 2.06 |
| Cash ratio | 3.86 | 3.97 | 5.22 | 3.30 | 2.42 | 5.28 | 0.39 | 1.20 | 0.88 | 0.77 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | 0.00 | 0.23 | 1.07 | 0.50 | 0.64 |
| Debt / Assets | - | - | - | - | - | 0.00 | 0.06 | 0.13 | 0.20 | 0.26 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.11 | 1.11 | 1.08 | 1.11 | 1.09 | 1.11 | 3.70 | 8.09 | 2.47 | 2.45 |
| Liabilities / Assets | 0.10 | 0.10 | 0.08 | 0.10 | 0.08 | 0.10 | 0.73 | 0.88 | 0.60 | 0.59 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.17 | 0.21 | 0.23 | - | 0.35 | 0.23 | 0.09 | - |
| Inventory turnover | 0.38 | - | 0.24 | 0.32 | 0.40 | - | 0.25 | 0.24 | 0.25 | - |
| Days sales outstanding | 207d | - | 244d | 239d | 257d | - | 226d | 175d | 182d | - |
| Days inventory outstanding | 958d | - | 1495d | 1158d | 915d | - | 1478d | 1518d | 1469d | - |
| Days payable outstanding | 338d | - | 297d | 519d | 208d | - | 209d | 788d | 601d | - |
| Cash conversion cycle | 827d | - | 1442d | 878d | 965d | - | 1496d | 905d | 1050d | - |
| Valuation | ||||||||||
| P / E | - | - | 537.5x | 194.3x | 424.3x | - | 150.5x | - | - | - |
| P / B | 3.0x | - | 3.7x | 5.2x | 6.3x | - | 34.1x | 56.6x | 8.1x | - |
| P / S | 13.4x | - | 20.9x | 22.7x | 25.4x | - | 26.1x | 30.6x | 37.8x | - |
| EV / EBITDA | - | - | - | 190.8x | 715.6x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 26.3% | - | 83.6% | 211.0% | 530.3% | - | 1136.2% | 874.4% | 425.8% | - |
| Revenue CAGR (3y) | 247.2% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 25.5% | - | 87.6% | 233.6% | 657.6% | - | 3076.1% | 1710.7% | 437.5% | - |
| Operating income growth (YoY) | - | - | 69.2% | - | - | - | 88.1% | 51.1% | -23.5% | - |
| Net income growth (YoY) | - | - | -55.5% | - | - | - | - | -90.8% | -23.5% | - |
| EPS growth (YoY) | - | - | -66.7% | - | - | - | - | 17.2% | 59.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -86.1% | - | - | - | - | - | - | - | -125.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 40.5% | 61.8% | 1239.9% | 2404.4% | 448.8% | 335.7% | -65.3% | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$85.23M totalHEPZATOKIT$78.83M · 92.5%
CHEMOSAT$6.40M · 7.5%
Geographic
$85.23M totalUS$78.83M · 92.5%
Non Us$6.40M · 7.5%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing DELCATH SYSTEMS against the 5 most active filers in the same SIC group.